TUFTS LINDA 4
4 · PhaseBio Pharmaceuticals Inc · Filed Oct 24, 2018
Insider Transaction Report
Form 4
TUFTS LINDA
Director
Transactions
- Exercise/Conversion
Series C-1 Preferred Stock
2018-10-22$0.12/sh+9,847$1,182→ 47,377 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (9,847 underlying) - Exercise/Conversion
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−991→ 0 total(indirect: By FSV II, LP)Exercise: $0.12→ Series C-1 Preferred Stock (991 underlying) - Purchase
Common Stock
2018-10-22$5.00/sh+1,277$6,385→ 59,429 total(indirect: By FSV II, LP) - Purchase
Common Stock
2018-10-22$5.00/sh+6,041$30,205→ 281,096 total(indirect: By FSV II-B, LP) - Exercise/Conversion
Warrants to Purchase Series B Preferred Stock
2018-10-22−710→ 0 total(indirect: By FSV II, LP)Exercise: $0.12→ Series B Preferred Stock (710 underlying) - Exercise/Conversion
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−4,690→ 0 total(indirect: By FSV II-B, LP)Exercise: $0.12→ Series C-1 Preferred Stock (4,690 underlying) - Conversion
Common Stock
2018-10-22+275,055→ 275,055 total(indirect: By FSV II-B, LP) - Exercise/Conversion
Warrants to Purchase Series B Preferred Stock
2018-10-22−7,053→ 0 total(indirect: By Fletcher Spaght Ventures II, LP)Exercise: $0.12→ Series B Preferred Stock (7,053 underlying) - Exercise/Conversion
Series B Preferred Stock
2018-10-22$0.12/sh+7,053$846→ 347,420 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (7,053 underlying) - Sale
Series B Preferred Stock
2018-10-22$5.00/sh−170$850→ 347,250 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (170 underlying) - Sale
Series B Preferred Stock
2018-10-22$5.00/sh−18$90→ 34,968 total(indirect: By FSV II, LP)→ Common Stock (18 underlying) - Exercise/Conversion
Warrants to Purchase Series B Preferred Stock
2018-10-22−3,359→ 0 total(indirect: By FSV II-B, LP)Exercise: $0.12→ Series B Preferred Stock (3,359 underlying) - Sale
Series B Preferred Stock
2018-10-22$5.00/sh−81$405→ 165,395 total(indirect: By FSV II-B, LP)→ Common Stock (81 underlying) - Exercise/Conversion
Series C-1 Preferred Stock
2018-10-22$0.12/sh+991$119→ 4,770 total(indirect: By FSV II, LP)→ Common Stock (991 underlying) - Exercise/Conversion
Series C-1 Preferred Stock
2018-10-22$0.12/sh+4,690$563→ 22,565 total(indirect: By FSV II-B, LP)→ Common Stock (4,690 underlying) - Conversion
Series AA Preferred Stock
2018-10-22−12,025→ 0 total(indirect: By FSV II, LP)→ Common Stock (12,025 underlying) - Conversion
Series D Preferred Stock
2018-10-22−63,688→ 0 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (63,688 underlying) - Conversion
Common Stock
2018-10-22+577,486→ 577,486 total(indirect: By Fletcher Spaght Ventures II, LP) - Conversion
Common Stock
2018-10-22+58,152→ 58,152 total(indirect: By FSV II, LP) - Exercise/Conversion
Series B Preferred Stock
2018-10-22$0.12/sh+710$85→ 34,986 total(indirect: By FSV II, LP)→ Common Stock (710 underlying) - Exercise/Conversion
Series B Preferred Stock
2018-10-22$0.12/sh+3,359$403→ 165,476 total(indirect: By FSV II-B, LP)→ Common Stock (3,359 underlying) - Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−237$1,185→ 47,140 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (237 underlying) - Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−113$565→ 22,452 total(indirect: By FSV II-B, LP)→ Common Stock (113 underlying) - Conversion
Series C-1 Preferred Stock
2018-10-22−47,140→ 0 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (47,140 underlying) - Purchase
Common Stock
2018-10-22$5.00/sh+12,682$63,410→ 590,168 total(indirect: By Fletcher Spaght Ventures II, LP) - Exercise/Conversion
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−9,847→ 0 total(indirect: By Fletcher Spaght Ventures II, LP)Exercise: $0.12→ Series C-1 Preferred Stock (9,847 underlying) - Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−24$120→ 4,746 total(indirect: By FSV II, LP)→ Common Stock (24 underlying) - Conversion
Series AA Preferred Stock
2018-10-22−119,408→ 0 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (119,408 underlying) - Conversion
Series B Preferred Stock
2018-10-22−347,250→ 0 total(indirect: By Fletcher Spaght Ventures II, LP)→ Common Stock (347,250 underlying) - Conversion
Series B Preferred Stock
2018-10-22−34,968→ 0 total(indirect: By FSV II, LP)→ Common Stock (34,968 underlying) - Conversion
Series C-1 Preferred Stock
2018-10-22−22,452→ 0 total(indirect: By FSV II-B, LP)→ Common Stock (22,452 underlying) - Conversion
Series D Preferred Stock
2018-10-22−6,413→ 0 total(indirect: By FSV II, LP)→ Common Stock (6,413 underlying) - Conversion
Series B Preferred Stock
2018-10-22−165,395→ 0 total(indirect: By FSV II-B, LP)→ Common Stock (165,395 underlying) - Conversion
Series C-1 Preferred Stock
2018-10-22−4,746→ 0 total(indirect: By FSV II, LP)→ Common Stock (4,746 underlying) - Conversion
Series AA Preferred Stock
2018-10-22−56,874→ 0 total(indirect: By FSV II-B, LP)→ Common Stock (56,874 underlying) - Conversion
Series D Preferred Stock
2018-10-22−30,334→ 0 total(indirect: By FSV II-B, LP)→ Common Stock (30,334 underlying)
Footnotes (4)
- [F1]Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]FSA II, LLC is the general partner of the general partner of Fletcher Spaght Ventures II, LP and FSV II-B, LP and the manager of the general partner of FSV II, LP. The reporting person is a managing member of FSA II, LLC and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- [F3]Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
- [F4]The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.